Skip to content

亨利希恩

US · HSIC #1526 按市值排名 上市于 1970
86.38 -0.61 -0.70%
实时 - 追踪5344个代码 - 心跳于360秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

高于合理价值
59.54 合理价值 ≈ 71.38 83.23
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为59.54-83.23。
  • 当前价格比按平均倍数计算的合理价值(71.38)高21.0%。

估值 各估值倍数与自身5年区间的对比

市净率 3.01 高于历史水平 第77百分位
5年平均 2.78 · 在Medical Distribution中排名第4/7
市盈率 24.87 高于历史水平 第83百分位
5年平均 21.83 · 前瞻 18.76 · 在Medical Distribution中排名第4/6
市销率 0.70 低于历史水平 第26百分位
5年平均 0.76 · 前瞻 0.67 · 在Medical Distribution中排名第8/12

同业对比 Medical Distribution

公司 市值 市盈率(TTM) 市净率 股息率
亨利希恩 (HSIC) 9.63B 25.18 3.05 0.00%
McKesson (MCK) 117.15B 26.83 -27.63 0.33%
Cencora (COR) 65.06B 25.31 21.32 0.69%
Cardinal Health (CAH) 58.83B 35.14 -20.41 0.81%
Akso Health (AHG) 1.16B -45.00 6.40 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值82.34 经济护城河Narrow 不确定性Medium

当前股价高于晨星合理价值估算4.7%。

合理价值

Henry Schein Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% premium over our quantitative fair value estimate of $82.34 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.

The firm's unfavorable dividend structure undermines our quantitative valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which falls in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.

Alternatively, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.6, for example, lies in the top 30% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

亨利希恩 讨论区 0 条评论

发表评论